KIORA PHARMACEUTICALS INC (KPRX) research
KIORA PHARMACEUTICALS INC- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.62
- As of
KIORA PHARMACEUTICALS INC (KPRX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
As of . Source: SEC EDGAR filings for KPRX. Method and limitations.
Share the KPRX intelligence card
See KPRX live in the terminal
Track KPRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live KPRX terminal, freeActive signals for KPRX
- highCONSENSUS_BUY
3 tracked funds increased KPRX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased KPRX this 2026Q2, institutional consensus
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in KPRX
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +418% to KPRX (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +641% to KPRX (2026Q2)
FREE, NO ACCOUNT
Every signal on KPRX, as it fires
You are seeing 5 of 20 signals recorded on KPRX since 2026-06-09.
The five above landed across 2 days. The other 15 were recorded on 3 other days. 11 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KPRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 49721T507 · 2026Q2 | $305K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 49721T507 · 2026Q2 | $234K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 49721T507 · 2026Q2 | $195K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 49721T507 · 2026Q2 | $78K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KPRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KPRX against its peers
KPRX's return on equity of -67.2% ranks in the 75th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | KPRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 172357 USD | 17 | 8 |
| Gross margin | n/a | 68.4% | n/a | 5 |
| Operating margin | n/a | -3269.4% | n/a | 7 |
| Net margin | n/a | -3209.7% | n/a | 7 |
| Return on equity | -67.2% | -120.5% | 75 | 17 |
Peers (20): IMRN, BCLI, PHIO, TOVX, BLRX, MTVA, ASBP, KALA, AZTR, VTGN, INAB, INTS, ICU, TPST, ANEB, QNRX, CKDXF, OTLC, ADIL, HIND. Left out: ENLV (no annual filing), LNAI (no annual filing), FBLG (no annual filing), MBRX (no annual filing), HOOK (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (KPRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more KPRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KPRXand get the insider, 13F, options, and confluence read in one view.